Relationship between post-transplant lymphoproliferative disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin

relationship between post-transplant lymphoproliferative disorder and anti-thymocyte globulin or anti-lymphocyte globulin

abstract background: lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. the principle risk factors for development of ptld are the degree of overall immunosuppression and the ebv serostatus of the recipient. in this study, the risk of ptld in kidney transplant recipients who received anti- ly...

Anti-thymocyte globulin induced thrombocytopenia.

Anti-thymocyte globulin is strongly reactive with platelets as measured by flow cytometric analysis. This reactivity appears to be independent of human leukocyte antigen (HLA) phenotype, is dose-dependent with saturation of platelet binding sites readily achieved with concentrations of horse anti-thymocyte globulin (ATG) at 0.25 mg per ml, and cannot be blocked with human anti-PLA1 antibody nor...

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant.

Severe graft-versus-host disease is a major barrier for non-T-cell-depleted haploidentical stem cell transplantation. There is no consensus on the optimal graft-versus-host disease prophylaxis. This study compared the two most commonly used graft-versus-host disease prophylaxis regimens (post-transplant cyclophosphamide-based vs. the anti-thymocyte globulin-based) in adults with acute myeloid l...

Production of a Standardized Anti-Lymphocyte Globulin.

Rheumatology 2001;40:1192 Anti-thymocyte globulin in scleroderma

SIR, The detailed study of aggressive immunosuppressive treatment of scleroderma by Stratton et al. [1] is of great interest. Certainly novel approaches are justified in a rheumatic disease which has proved resistant to all forms of treatment. Indeed my colleagues and I instituted a similar trial of anti-thymocyte in combination with other immunosuppressive drugs which was reported in a confere...

Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.

BACKGROUND A combination of horse anti-thymocyte globulin and cyclosporine produces responses in 60-70% of patients with severe aplastic anemia. We performed a phase II study of rabbit anti-thymocyte globulin and cyclosporine as first-line therapy for severe aplastic anemia. DESIGN AND METHODS Twenty patients with severe aplastic anemia treated with rabbit anti-thymocyte globulin were compare...